Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
November 23, 2015
Lower open expected. RegMed’s pre-open, the sector has spiked higher as we await the next inversion
November 20, 2015
RegMed’s close: week-over-week variations are causing investor inertia and speculator devilment
November 20, 2015
US stocks to open higher. RegMed’s pre-open, confidence and conviction are AWOL
November 19, 2015
RegMed’s close: too frequently, the gain is followed by pain
November 19, 2015
Higher open is expected. RegMed’s pre-open, it’s very much a whipsaw sector
November 18, 2015
RegMed’s close: seized the upside but, where is the line in the sand of support?
November 18, 2015
Lower open is expected. RegMed’s pre-open, the revolution of the carousel is not helping the sector
November 17, 2015
RegMed’s close: divergent trading is confusing investors
November 17, 2015
A positive open is expected. RegMed’s pre-open, pricing sustainability has become a challenge as even traders become pickier
November 16, 2015
RegMed’s close: a day of anything goes and it did, then the sector ended neutral
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.